Caregility and Eko Partner to Bring Smart Stethoscope Technology to Award-Winning Enterprise Telehealth Platform

Caregility, an enterprise telehealth platform company, and Eko, the market leader in stethoscopes for telehealth, today announced an integration partnership. Caregility’s cloud platform now seamlessly integrates with Eko’s smart stethoscopes and software, enabling users of Caregility’s iConsult application to perform high-quality auscultation (heart, lung, and other body sounds) on patients during a virtual physical exam.

“Our partnership addresses a key component missing from most virtual exams – auscultation. The ability for care teams to easily and accurately assess a patient’s body sounds in real-time will have a meaningful impact on our hybrid care delivery models, including telenursing, telerounding, tele-ICU, and at-home care,” said Peter McLain, Chief Strategy Officer and SVP of Business Development at Caregility. “Eko’s unparalleled digital stethoscope sound quality and waveform visualization software will build clinician confidence, reduce workflow friction, and ultimately improve patient outcomes.”

This partnership integrates Eko Connect, Eko’s suite of telehealth APIs, with Caregility Cloud™. Caregility’s award-winning telehealth solution now has access to live-streaming stethoscope sounds with real-time phonocardiogram (PCG) and electrocardiogram (ECG)* waveform visualization within a familiar interface. The integration is compatible with Eko’s complete line of smart stethoscopes, including the CORE Digital Stethoscope Attachment, 3M™ Littmann® CORE Digital Stethoscope, and DUO ECG + Digital Stethoscope.

During an iConsult virtual care session, care teams can quickly and easily collaborate to perform a complete stethoscope examination on a patient. Users wirelessly connect an Eko stethoscope directly with a Caregility APS telehealth device or tablet with just one touch. This streamlined workflow eliminates additional workflow complexities and allows the care team to stay within Caregility’s iConsult application to focus on conducting a high-quality virtual visit.

“Caregility and Eko share a mission to provide healthcare professionals and institutions with technologies that enable them to give their patients the best care possible, in-person or remote,” said Jason Bellet, Co-founder and Chief Strategy Officer at Eko. “By marrying our Eko Connect solution with Caregility’s virtual care platform, we’re redefining the virtual physical exam experience for hundreds of health systems, thousands of clinicians, and millions of patients.”

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”
Exit mobile version